Drug intelligence / Profile preview

ABBV-932

Development stage: Phase 2
Lead developer: AbbVie
Modality: Small Molecules
Administration: Oral

Overview

ABBV-932 is an investigational small molecule drug developed by AbbVie, in partnership with Gedeon Richter, for the treatment of bipolar disorder and generalized anxiety disorder. It acts as a selective modulator of dopamine D3 and D2 receptors, with a preference for the D3 receptor. The drug is being studied as a monotherapy for depressive episodes in adults with bipolar I or II disorder and is also under investigation for generalized anxiety disorder and schizophrenia. ABBV-932 is administered orally in capsule form and has reached Phase 2 clinical trials for both bipolar disorder and generalized anxiety disorder[1][4][5][8].

Other names: ABBV-932ABBV932ABBV 932

Targets

DRD3 (Dopamine receptor D3)DRD2 (Dopamine D2 Receptor)

Beyond the preview

Go deeper on ABBV-932.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ABBV-932.

Explore the full profile